EP4543456A1 — Preservative-free ophthalmic composition comprising a prostaglandin analogue
Assigned to Zaklady Farmaceutyczne "polpharma" Spolka Akcyjna · Expires 2025-04-30 · 1y expired
What this patent protects
The present invention relates to a preservative-free ophthalmic composition comprising a prostaglandin analogue for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days. The composition remains microbiologically acceptable while in u…
USPTO Abstract
The present invention relates to a preservative-free ophthalmic composition comprising a prostaglandin analogue for use in the reduction of elevated intraocular pressure during a treatment period of at least 90 days. The composition remains microbiologically acceptable while in use during said treatment period, as assessed in a microbiological test comprising repeated microbial challenge with four microorganisms consisting of one gram-negative bacterium, one gram-positive bacterium, one fungus of the Aspergillus genus and Candida albicans.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.